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Chicken cathelicidin-2 (CATH-2) is a host defense peptide that exhibits immunomodulatory and anti-
bacterial properties. Here we examined effects of CATH-2 in zebraﬁsh embryos in the absence and
presence of infection. Yolk-injection of 0.2e1.5 h post-fertilized (hpf) zebraﬁsh embryos with 2.6 ng/kg
CATH-2 increased proliferation of phagocytic cells at 48 hpf by 30%. A lethal infection model was
developed to test the prophylactic protective effect of CATH-2 peptide. Embryos (0.2e1.5 hpf) were
injected with 2.6 ng/kg CATH-2, challenged with a lethal dose of ﬂuorescently labeled Salmonella
enteritidis pGMDs3 at 28 hpf and monitored for survival. Prophylactic treatment with CATH-2 was found
to delay infection starting at 22 h post-infection (hpi). At 18e20 hpi, signiﬁcantly lower (2-fold) ﬂuo-
rescence intensity and decreased bacterial loads were detected in peptide-treated embryos. Thus pro-
phylactic administration of low CATH-2 concentrations confer partial protection in zebraﬁsh embryos by
boosting the innate immune system.
© 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Host defense peptides (HDP) are key players in the primary
defense of the innate immune system and are considered to have
potential as new broad-spectrum antimicrobial agents (Hancock
and Sahl, 2006). Chicken cathelicidin-2 (CATH-2) is one of the
four cathelicidins known in chicken (Goitsuka et al., 2007; van Dijk
et al., 2005; Xiao et al., 2006). CATH-2 is a short (26 amino acids),
cationic peptide with amphipathic properties that has been shown
to exhibit antibacterial activity at micromolar level (van Dijk et al.,
2009; Veldhuizen et al., 2013). Besides its microbicidal activity, this
peptide is gaining considerable interest due to its immunomodu-
latory properties. In vitro it has been demonstrated that CATH-2
neutralizes LPS and induces human monocyte chemoattractant
protein-1 (MCP-1) in PMBCs (van Dijk et al., 2009). As in vitro cul-
tures often do not resemble the complex in vivo situation, studies in
animal models are crucial to investigate the function of HDPs.Diseases and Immunology,
ry Medicine, Utrecht Univer-
ds.
an).
Ltd. This is an open access article uVarious HDPs have already been tested in in vivo models,
showing that immunomodulation instead of directmicrobial killing
activity of a peptide is often essential in order to eliminate an
invading pathogen (Hilchie et al., 2013). A clear example of an
immunomodulatory mode of action of HDPs in vivo was described
for the innate defense regulator-1 (IDR-1) peptide. Despite its lack
of antimicrobial activity in vitro, it can protect mice from bacterial
infections. In these studies it was demonstrated that IDR-1 treated
mice were more protected from bacterial infections, because the
peptide elicited elaborate immune responses in macrophages and
monocytes to clear the infection (Scott et al., 2007). Similarly LL-37,
the only human cathelicidin, is known to have low antimicrobial
activity in vitro (MIC values 32e64 mg/ml). However, in vivo tests
have shown that the bacterial load decreased in mice treated with
LL-37, suggesting that triggering the immune system seems to be a
key factor to eradicate invading pathogens (Bowdish et al., 2005).
Zebraﬁsh are commonly used as an in vivo model, because they
have a large number of offspring that develop externally, rapidly
and are optically transparent (van der Sar et al., 2004). Further-
more, zebraﬁsh have an innate and adaptive immune system,
whereby the latter is not fully functional in zebraﬁsh embryos
during the ﬁrst weeks. (Trede et al., 2004). Their ﬁrst line of defensender the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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phils, which emerge in the ﬁrst two days post-fertilization
(Crowhurst et al., 2002; Herbomel et al., 1999; Willett et al.,
1999). Due to these immunological features, zebraﬁsh embryos
are a suitable host model to study the innate immunomodulatory
properties of HDPs.
The objective of this study was to investigate the immuno-
modulatory activity of CATH-2 in vivo. Using the zebraﬁsh embryo
model we determined the toxicity of the peptide and the effect of
CATH-2 on immune cells was explored. Lastly, the prophylactic
protective effect of CATH-2 against bacterial infections in zebraﬁsh
embryos was determined. Our results showed a protective immu-
nostimulatory effect of CATH-2 in Salmonella enteritidis infected
zebraﬁsh embryos, due to a peptide-induced increase of phagocytic
cells.2. Materials and methods
2.1. Peptide
Synthetic CATH-2 peptides (RFGRFLRKIRRFRPKVTITIQGSARF-
NH2) were custom made at CPC Scientiﬁc Inc. (Sunnyvale, CA) and
were of >95% purity. The peptides were endotoxin-free. Peptide
concentrations were made by diluting CATH-2 with injection
buffer, a phosphate buffered saline (PBS) containing 1.48 mM
NaH2PO4, 8.06 mM Na2HPO4 and 20 mM NaCl (pH ¼ 7.27). For all
experiments CATH-2 was used in its D-form. D-peptides have been
shown to have a higher stability in vivo, as they are more resistant
against proteolytic degradation than peptides in L-form (Molhoek
et al., 2011; Wade et al., 1990).2.2. Zebraﬁsh embryos and injections
For all experiments embryos from the transparent mutant
zebraﬁsh line casperwere used, which are lacking melanocytes and
iridophores (White et al., 2008). Zebraﬁsh embryos were harvested
from laboratory-breeding animals, which were maintained at 26 C
in aerated 5 L tanks on a 10:14 h light on/light off cycle. Embryos
were collected and kept at 31.5 C until 28 h post-fertilization (hpf).
Afterwards embryos were staged at 28 C for their further devel-
opment. Depending on the experimental set-up early stage em-
bryos (1e16 cell stage, 0.2e1.5 hpf) or 28 hpf embryoswere used for
microinjection. Early stage embryos were transferred in agarose
trays containing egg water (60 mg/ml instant ocean sea salts)
immediately after harvesting the eggs. Zebraﬁsh embryos at 28 hpf,
were ﬁrst mechanically dechorionated and then transferred to
agarose trays containing egg water and 0.02% (w/v) buffered 3-
aminobenzoic acid (Tricaine; Sigma-Aldrich), to anesthetize the
embryos. After positioning early stage and 28 hpf embryos in the
agarose trays, the embryos were used for injection purposes. Danio
rerio (zebraﬁsh) were handled in compliance with the local animal
welfare regulations and maintained according to standard pro-
tocols (zﬁn.org). The breeding of adult ﬁsh was approved by the
local animal welfare committee (Animal Experimental licensing
Committee, DEC) of the VU University medical center. All protocols
adhered to the international guidelines speciﬁed by the EU Animal
Protection Directive 86/609/EEC, which allows zebraﬁsh embryos
to be used up to themoment of free-living (approximately 5e7 days
after fertilization). Because embryos used in this study met these
criteria, this speciﬁc study was therefore approved by the Animal
Experimental Licensing Committee of the VU University medical
center (Amsterdam, the Netherlands).2.3. Toxicity studies of CATH-2
Two different stages (1e16 cell stage [0.2e1.5 hpf] weighed with
chorion 2.5 mg and 28 hpf weighed without chorion 0.3 mg) of
embryonic development were used for testing the toxic effects of
CATH-2. Depending on the developmental stage, embryos were
injected in the yolk with various concentrations of the peptide:
6.4 fg (2.6 ng/kg in 0.2e1.5 hpf and 21 ng/kg in 28 hpf embryos),
64.1 fg (25.6 ng/kg in 0.2e1.5 hpf and 210 ng/kg in 28 hpf embryos),
6.41 pg (2.6 mg/kg in 0.2e1.5 hpf and 21 mg/kg in 28 hpf embryos)
and 641 pg (256.4 mg/kg in 0.2e1.5 hpf and 2 mg/kg in 28 hpf
embryos) or injection buffer. Embryo survival was controlled a few
hours after injection and on a daily basis up to ﬁve days.
2.4. Whole-mount immunohistochemistry and confocal imaging of
peptide treated embryos
To determine the number of phagocytic cells in the embryonic
tail, cells were stained with L-plastin antibodies (a kind gift of Prof.
P. Martin, Bristol University, UK). L-plastin is a leukocyte speciﬁc
antibody, and tags both macrophages and neutrophils at 48 hpf (Le
Guyader et al., 2008; Redd et al., 2006). To this end 1e16 cell stage
(0.2e1.5 hpf) zebraﬁsh embryos were microinjected with 2.6 ng/kg
CATH-2 or injection buffer in the yolk. At 48 hpf the embryos were
anesthetized and ﬁxed with 4% paraformaldehyde (PFA; EMS)
overnight at 4 C. Embryos were rinsed several times for 10 min in
PBTx (PBS with 1% Triton X-100) and permeabilized with a pre-
chilled trypsin solution (0.24% in PBS buffer) on ice. After
washing the embryos 10 times for 10 min, the embryos were
incubated for 3 h with blocking buffer (10% normal goat serum
diluted in 1% PBTx) at room temperature (RT). Zebraﬁsh embryos
were incubated with anti-L-plastin, diluted 1:500 in antibody
buffer [PBTx with 1% (v/v) normal goat serum and 1% (w/v) bovine
serum albumin] for 1 h at RT. Subsequently, embryos were exten-
sively washed with PBTx and blocked for 1 h at RT. Finally, embryos
were incubated overnight at 4 C with ﬂuorescently labeled Goat
anti-Rabbit antibody (Alexa-Fluor-488, Invitrogen), diluted 1:200
in antibody buffer, and again washed in PBTx. Zebraﬁsh embryos
were embedded in 1% low-melting agarose (Sigma-Aldrich) and z-
stack analysis was performed of the tail close to the posterior blood
island on a Leica SPE-II confocal microscope at the Center for Cell
Imaging, University Utrecht. Subsequently, all cells were analyzed
with the Image J/Fiji software and green ﬂuorescent phagocytic
cells were counted by eye.
2.5. Bacterial strain, growth condition and transformation
Salmonella enteritidis phage type 13a was transformed with the
pGMDs3 (van der Sar et al., 2003). Bacteria were stored in glycerol
stocks and grown in LB-broth and LB-plates (Lennox, BD Difco™)
containing 100 mg/ml ampicillin (Sigma-Aldrich). Injection stocks
with 20% glycerol were made frommid-log phase bacteria in 10 ml
ampicillin-LB-broth. Finally, bacteria were washed in Dulbecco's
phosphate-buffered saline (DPBS; GIBCO) and diluted 1:100,000.
For visualization purposes during injections, bacteria were resus-
pended 1:1 with 0.17% (v/v) phenol red (Sigma-Aldrich) in PBS (pH
7.4; 136.9 mM NaCl, 2.68 mM KCl, 6.46 mM Na2HPO4 and 2.94 mM
KH2PO4).
2.6. Antibacterial activity of CATH-2
Colony counting assays were used to determine the direct
antibacterial activity of CATH-2 against Salmonella enteritidis
pGMDs3. Bacteria were grown to mid-logarithmic phase and after
washing the cells once in ampicillin-LB-broth diluted to
Fig. 1. High concentrations of CATH-2 have toxic effects in early stage embryos. Pools
of 20 embryos, at the 1e16 cell stage (0.2e1.5 hpf; A) and 28 hpf (B), were injected in
the yolk with various concentrations of CATH-2. Embryos were monitored for survival
(and development) 7 h after injection and afterwards daily for ﬁve days. All experi-
ments were performed at least in triplicate (data represent the mean ± S.E.M).
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(0e40 mM) were incubated for 3 h at 37 C. After serially diluting
(50e5000 fold) the mixtures, 100 ml per sample was spread plated
on Tryptone Soya Agar (TSA; Oxoid Limited) plates containing
100 mg/ml ampicillin and after 16 h at 37 C colonies were counted.
2.7. Determination of optimal infection dose
In order to determine the optimal infection dose, 28 hpf em-
bryos were infected via caudal vein injections with various con-
centrations of S. enteritidis pGMDs3, ranging from 1 to more than
500 CFUs (Benard et al., 2012). Groups of 15 embryos were used per
bacterial dose. Embryos were maintained after injection at 28 C
and monitored regularly for their rate of survival under the mi-
croscope the next day.
2.8. Prophylaxis studies
Immediately after harvesting 1e16 cell stage (0.2e1.5 hpf)
zebraﬁsh embryos were microinjected with 1 nl CATH-2 (2.6 ng/kg
to 260 mg/kg). On average 28 embryos were used per peptide
concentration, injection buffer or uninjected control. Embryoswere
kept at 31.5 C overnight and at 28 hpf embryos were systemically
infectedwith S. enteritidis pGMDs3 in the caudal vein. After keeping
the embryos at 28 C overnight, embryos were anesthetized and
the severity of the S. enteritidis pGMDs3 infection was monitored
using a Leica MZ16FA Fluorescence Stereo microscope. Fluores-
cence and bright-ﬁeld pictures were taken with a Leica DFC420C
camera and the ﬂuorescent intensity of the pictures was analyzed
with the eLaborant software (www.eLaborant.com). To determine
the bacterial load per zebraﬁsh embryo, each embryo was anes-
thetized and mashed in an Eppendorf tube containing egg water
solution. The embryos were further diluted in egg water solution
and plated on ampicillin LB plates. Plates were incubated for
16e20 h at 37 C and colonies were counted the next morning. In
addition, rate of survival studies were performed. For this the sur-
vival (heart-beating) of S. enteritidis challenged embryos, which
were pre-injected with buffer or CATH-2, was monitored regularly
by eye.
2.9. Graphs and statistical analysis
The graphs in this manuscript were made with the GraphPad
Prism 5.0 software. Statistical analyses were performed using one-
way analysis of variance (ANOVA) and Dunnett's post hoc test.
Signiﬁcant differences were indicated as * (P < 0.05), ** (P < 0.01) or
*** (P < 0.001). To analyze the survival curves for the prophylaxis
studies, a cutoff value of 22 h was used to dichotomize the interval
from injection of the ﬁrst ﬁsh in the group till moment of death. A
logistic regression analysis was applied with binary variable “death
within 22 h” as outcome and experiment as random effect to take
the correlation between observations within experiments into ac-
count (Bates et al., 2014). Treatment was added to the model as
explanatory variable. The Akaike's Information Criterion was used
to select the best model. R version 3.1.2 (R Core team, 2014) was
used for this analysis.
3. Results
3.1. CATH-2 toxicity studies in zebraﬁsh embryos
In order to determine the toxicity of CATH-2, various concen-
trations of the D-amino acid analog of chicken cathelicidin-2 were
yolk-injected in early stage (0.2e1.5 hpf) or 28 hpf embryos. Con-
centrations ranging from 2.6 ng/kg to 2.6 mg/kg did not affect thesurvival and development of early stage embryos. However, CATH-
2 proved to be lethal to embryos at the highest concentration tested
(260 mg/kg). At this dose 50% of early stage embryos died within 7 h
after injection (Fig. 1A). Toxicity of CATH-2 was also tested in one-
day old embryos (28 hpf). No toxic effects of the different peptide
concentrations were observed. Five days post-injection more than
80% of the embryos survived even the highest concentration of
2 mg/kg CATH-2 used (Fig. 1B).
3.2. Phagocytic cell proliferation
To elucidate the immunomodulatory effect of CATH-2 injection
in early stage (0.2e1.5 hpf) embryos, immunohistochemistry on
phagocytic cells was performed on CATH-2 treated 48-h old em-
bryos (Fig. 2A). Macrophages and neutrophils were stainedwith the
L-plastin antibody and their numbers quantiﬁed (Fig. 2B). Inter-
estingly, relative to untreated or buffer injected embryos a 30%
increase in phagocytic cells was observed in embryos that received
2.6 ng/kg CATH-2 (Fig. 2C). These results suggest that CATH-2 has
an immunostimulatory effect by increasing the amount of phago-
cytic cells in embryos.
3.3. Embryo infection with S. enteritidis pGMDs3
In order to determine whether the observed increase in
phagocytic cells could lead to increased protection against bacterial
infections, a S. enteritidis pGMDs3 infection model was developed.
To this end, embryos (28 hpf) were infected with various doses of
S. enteritidis pGMDs3 via caudal vein injection. Concentrations
exceeding 500 CFUs were lethal to embryos within 17 h post-
infection (hpi). Embryos infected with 51e500 CFUs had a very
rapid infection progression and were therefore harder to monitor.
With this infectious dose approximately 50% of the embryos had
died already 17 hpi and at 25 hpi all embryos had succumbed to the
infection. When challenged with 10e50 CFUs more than 80% of the
embryos survived at 17 hpi, and 23% of these embryos were still
alive at 25 hpi. In the lowest concentration tested (1e9 CFUs) 50% of
the embryos survived even after 39 hpi, which may indicate self-
clearance of the infection (Fig. 3). These results showed that
S. enteritidis pGMDs3 is lethal for 28 hpf zebraﬁsh embryos and
Fig. 2. CATH-2 enhances the number of phagocytic cells in zebraﬁsh embryos. Diagram
of a 48 hpf embryo with the area, highlighted in a red box, which was used to measure
phagocytic cells (A). Early stage (0.2e1.5 hpf) embryos were treated with CATH-2 and
macrophages and neutrophils were visualized in green using a L-plastin antibody (B)
and counted (C) (n ¼ 3, in average 9 embryos per group, bar ¼ mean ± S.E.M is
depicted). ***p < 0.001, one-way ANOVA, multiple comparison.
Fig. 3. S. enteritidis pGMDs3 is lethal for zebraﬁsh embryos. Groups of 10e15 trans-
parent zebraﬁsh embryos (28 hpf) were systemically infected with various doses of
S. enteritidis pGMDs3. Embryos were monitored 17 hpi and at regular intervals
thereafter. The survival curves represent the mean ± S.E.M of three independent ex-
periments per inoculum class.
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the infection in zebraﬁsh embryos one day after infection.
3.4. Prophylactic effect of CATH-2 on S. enteritidis infection
The proposed prophylactic effect of CATH-2 in zebraﬁsh em-
bryos was tested by injecting various concentrations of CATH-2 into
the yolk of early stage (0.2e1.5 hpf) embryos and to subsequently
systemically challenge these embryos with S. enteritidis pGMDs3 at
28 hpf. To determine the effect of CATH-2 in the early phase of
infection, the bacterial infection in the embryos was analyzed by
confocal microscopy. The ﬂuorescent signal of S. enteritidis pGMDs3
in the embryos was monitored 18 to 20 hpi. Embryos, which were
treatedwith CATH-2, had a lower ﬂuorescent intensity compared to
the control groups (Fig. 4A and Fig. S1). The measured ﬂuorescent
intensity level of CATH-2 injected embryos was signiﬁcantly (two-
fold) lower than observed for untreated and buffer injected em-
bryos. The median values of the pixel count demonstrated even a
two-log-reduction in CATH-2 pre-injected embryos compared to
the control groups (Fig. 4B).
Additional plating of embryos at 20e22 hpi on agar media
revealed that prophylactic administration of 2.6 ng/kg CATH-2 into
the yolk resulted in a signiﬁcantly two-fold reduction of bacterial
survival in embryos. Median values conﬁrmed these ﬁndings, as
again a two-fold lower CFU count was observed in peptide pre-
injected embryos (Fig. 4C).
Next the rate of survival of S. enteritidis infected embryos, which
were pretreated with CATH-2, was monitored. Although prophy-
lactic treatment with CATH-2 did not prevent mortality, a signiﬁ-
cant delay in the progression of infection could be observed 22 hpi
for embryos treated with 2.6 ng/kg CATH-2 (Fig. 5). Quantiﬁcation
of the effect using logistic regression showed that the odds on
death within 22 h for untreated embryos was 1.9 times larger (95%
CI: 1.1e3.2) than the odds for the buffer pre-injected group. For
2.6 ng/kg, 25.6 ng/kg and 2.6 mg/kg, oddswere 0.5 (95% CI: 0.3e0.9),
0.7 (95% CI: 0.3e1.5) and 0.7 (95% CI: 0.4e1.3) relative to the buffer
pretreated embryos respectively. Fig. 5 is a result from six pooled
independent experiments, only in one experiment the buffer
injected embryos, showed a higher survival compared to the pep-
tide injected embryos at 110 hpi.
4. Discussion
In this study we demonstrated for the ﬁrst time the in vivo ac-
tivity of CATH-2 peptide. Our data showed that prophylactic CATH-
2 administration in the yolk of zebraﬁsh embryos led to a partial
protection against lethal bacterial infections. Zebraﬁsh are an
established in vivomodel, which has been extensively used to study
host-pathogen interactions and to model various diseases (Meijer
et al., 2014; van Leeuwen et al., 2014). Furthermore, zebraﬁsh
embryos have been used to determine the toxicity and mode of
action of various biochemical and biological compounds
(Berghmans et al., 2008; Fleming A., 2013; Ordas et al., 2015;
Rubinstein, 2006). This model has, however, to the best of our
knowledge, not yet been used to study the effect of HDPs on
infection in vivo. To date only one study reports on the use of HDPs
in zebraﬁsh embryos to test cytotoxicity of such peptides. In this
study magainin-2, pleurocidin and pleurocidin derived peptides
were tested for their cytotoxic effects towards 4, 28 and 52 hpf
zebraﬁsh embryos, when added to the water (Morash et al., 2011).
Such compound screening on zebraﬁsh embryos has indeed mainly
been performed by adding the compound to the water (Goldsmith,
2004; Ordas et al., 2015; Ridges et al., 2012; Zon and Peterson,
2005). This administration route has the disadvantage that com-
pound uptake through the skin can be limited and is dependent on
Fig. 4. CATH-2 decreases the bacterial load in embryos. Groups of 10 embryos received
either 2.6 ng/kg CATH-2 or buffer by yolk injection at 1e16 cell stage (0.2e1.5 hpf)
followed by challenge with S. enteritidis pGMDs3 at 28 hpf. Fluorescence intensity was
monitored at 18e20 hpi. Bright-ﬁeld and ﬂuorescent images of two representative
embryos per condition are shown (A). Images were further analyzed based on their red
ﬂuorescent pixel counts (B) (n ¼ 4, 10 embryos per group, mean is depicted). CFUs of
the S. enteritidis pGMDs3 infected embryos were determined 20e22 hpi (n ¼ 4, 10
embryos per group, mean and median are depicted black and red bar, respectively) (C).
*p < 0.05, **p < 0.01. A log-transformation was applied on the CFU and pixel data to
obtain normally distributed data. Statistical analysis was performed using one-way
ANOVA, multiple comparison.
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of compounds, as performed in the current study, circumvents this
problem of inadequate uptake efﬁcacies.
Toxic effects of micro-injection of CATH-2 were analyzed at two
different developmental stages of the zebraﬁsh (1e16 cell stage and
28 hpf). Only a relatively high concentration of CATH-2 (260 mg/kg)
was toxic for early stage embryos (Fig. 1A). At the early point of
development embryos consist only of a few cells (1e16 cells). In
contrast at 28 hpf embryos are more developed, at that time they
have a beating heart, blood circulation, pigmentation of their eyes
and a straight tail (Benard et al., 2012; Kimmel et al., 1995). These
later stage embryos were less susceptible to high peptide concen-
trations, exhibiting only low toxic effects with 2 mg/kg CATH-2
(Fig. 1B).
To investigate the immunostimulatory properties of CATH-2, the
peptide was injected in early stage zebraﬁsh embryos. Immuno-
histochemistry with L-plastin antibody was performed to detect
macrophages and neutrophils in 48 hpf embryos upon pre-
injection with CATH-2 at early cell stage. Injection of the peptide
led to a signiﬁcant 30% increase of these phagocytic cells in CATH-2
injected embryos compared to the control group (Fig. 2C).
To study the prophylactic activity of HDPs in vivo, a novel
approach was developed by combining peptide micro-injections in
early stage zebraﬁsh embryos and challenging the same embryos at
28 hpf by caudal blood vein injection. These experiments showed a
prophylactic potential of CATH-2 against bacterial infection. Both
CFU and pixel counts demonstrated a signiﬁcant two-fold decrease
in CATH-2 pretreated embryos compared to the untreated control
groups (Fig. 4). In addition, the survival rate of the embryos was
monitored. At 22 h post-infection a signiﬁcant delay in the pro-
gression of infection could be observed in 2.6 ng/kg of CATH-2
zebraﬁsh embryos (Fig. 5). Colony counting assays using
S. enteritidis pGMDs3 have shown that CATH-2 has a minimal
inhibitory concentration (MIC) value of 10 mM (Fig. S2). Due to the
low peptide concentrations used for the zebraﬁsh experiments a
direct killing effect of CATH-2 in vivo is unlikely. Taken together
these ﬁndings suggest that a peptide-induced increase in phago-
cytic cells may contribute to the prophylactic effect of CATH-2 in
the infections experiments.
Interestingly, 2.6 ng/kg seemed to be the optimum concentra-
tion during this study as higher peptide concentrations led to a
lower survival rate. At a dose of 2.6 ng/kg D-CATH-2 recruitment of
phagocytic cells occurs. Chemotaxis has been reported to be highly
concentration dependent, i.e. immune cells will react to chemo-
tactic ligands within a limited concentration range (De et al., 2000).
It maywell be that the higher concentrations tested are beyond this
range. Several other explanations can be offered for the observation
that higher peptide concentrations (25.6 ng/kg and 2.6 mg/kg) have
less prophylactic effects. A high peptide concentrationmay result in
speciﬁc detrimental effects on immune cells during infection.
Another possibility is that at higher peptide concentrations the
anti-inﬂammatory properties of CATH-2 prevail and cause
disabling of the immature immune system.
During these studies also the L-form of CATH-2 was tested.
Toxicity experiments with the L-form of CATH-2 showed similar
results at all concentrations described as with the D-CATH-2. Only
with the highest concentration of L-CATH-2 (260 mg/kg) toxic ef-
fects were observed in early stage embryos already 7 h post-
injection (data not shown). In addition, the rate of survival of L-
CATH-2 pre-injected embryos upon bacterial challenge was moni-
tored, showing that the protective effect of L-CATH-2 against
infection indicates the same tendency but was less strong
compared to D-CATH-2 pre-injected embryos (data not shown).
These ﬁndings support our hypothesis that the D-form of the
peptide is more stable in vivo than the L-form.
Fig. 5. CATH-2 delays the infection in zebraﬁsh embryos in their early phase of
infection. Embryos were injected with various concentrations of CATH-2 or buffer at
1e16 cell stage (0.2e1.5 hpf) and were challenged with 10e100 CFUs of S. enteritidis
pGMDs3 at 28 hpf. Embryos were monitored for survival at 16 hpi and at regular in-
tervals thereafter. Kaplan Meyer survival analysis was based on the pooled data of six
independent experiments (n ¼ 6, on average 28 embryos per group).
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rable immunomodulatory properties of HDPs in vivo (Bommineni
et al., 2014; Elahi et al., 2006; Lisanby et al., 2008). One such pep-
tide is human neutrophil peptide-1 (HNP-1), which has antibacte-
rial activity and was proven to be effective in mice where it
demonstrated high activity against Klebsiella pneumoniae and
Staphylococcus aureus infections. Low doses (0.4 ng) of HNP-1 were
sufﬁcient to rescue mice from bacterial infections and this activity
was related to the presence of neutrophils since no effect was
observed for neutrophil depleted mice (Welling et al., 1998).
Similarly, in vivo studies were performed on various innate defense
regulator (IDR) peptides, which are derived from natural antimi-
crobial peptides but lack antimicrobial activity. These peptides
show immunomodulatory properties by recruiting monocytes,
macrophages or neutrophils during infection (Nijnik et al., 2010;
Scott et al., 2007). These studies including our current ﬁndings all
point towards an important role for HDPs in innate immunity
related to numbers and activity of neutrophils or macrophages and
possibly other innate immune cells.
In conclusion, microinjection in zebraﬁsh embryos was used for
the ﬁrst time as a method to study in vivo immunostimulatory and
prophylactic effects of a HDP. At low doses CATH-2 was found to
stimulate the immune system of zebraﬁsh embryos by enhancing
the proliferation of phagocytic cells. This increased amount of
phagocytic cells is thought to be crucial in lowering bacterial sur-
vival and postponing the infection in S. enteritidis infected zebraﬁsh
embryos.
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